Black, Hispanic and Medicaid-insured populations continue to lack equitable access to pre-exposure prophylaxis, according to new findings from Gilead Sciences presented at IDWeek 2024.
Black, Hispanic and Medicaid-insured populations continue to lack equitable access to pre-exposure prophylaxis, according to new findings from Gilead Sciences presented at IDWeek 2024.
The Infectious Diseases Society of America has released guidelines suggesting the use of pemivibart to prevent severe COVID-19 in immunocompromised patients.
The Senate FY 2025 Labor, Health and Human Services and the State and Foreign Operations appropriations bills provide increased funding for some key domestic and global infectious diseases programs.
The eight awarded institutions have created stewardship programs led by infectious diseases-trained physicians and pharmacists that advance science in antimicrobial resistance.
Trish Perl, MD, FIDSA, spoke on behalf of the Infectious Diseases Society of America at Thursday’s House Budget Committee roundtable on the threats of antimicrobial resistance.
The House FY 2025 Labor, Health and Human Services and State and Foreign Operations appropriations bills largely flat fund antimicrobial resistance programs at FY 2024 levels even as AMR grows as a serious public health threat.
The Centers for Medicare and Medicaid Services released its calendar year 2025 Medicare Physician Fee Schedule Proposed Rule July 10, including a new “add-on” code for infectious diseases developed and advocated for by IDSA.
The Infectious Diseases Society of America has released new guidelines on complicated intra-abdominal infections in children, adults and pregnant people.
IDSA and HIVMA welcome the Centers for Disease Control and Prevention’s guidelines for implementing doxycycline as post-exposure prophylaxis, or doxy PEP, to prevent sexually transmitted infections.
IDSA and HIVMA are disappointed and alarmed that Uganda’s Constitutional Court upheld the Anti-Homosexuality Act criminalizing LGBTQ individuals and their right to organize, educate and advocate. We are deeply concerned by the impact of the law on Uganda’s HIV response and for people with HIV and vulnerable to HIV in the country.
IDSA is encouraged that the president’s FY 2025 Budget Request proposes deeper investments in several key IDSA priorities, including the CDC Antibiotic Resistance Solutions Initiative (to prevent, detect, track and contain antimicrobial resistance) and the National Institute of Allergy and Infectious Diseases, though IDSA is advocating for even larger funding increases for these priorities.
The legislation averts proposed cuts to the National Institute of Allergy and Infectious Diseases and other ID/HIV programs. The bill also includes a one-year extension of expired President’s Emergency Plan for AIDS Relief provisions. IDSA continues to urge Congress to provide sufficient funding in FY 2025 for ID and HIV programs.